Arvinas Inc
(NAS:ARVN)
$
31.37
-1.36 (-4.16%)
Market Cap: 2.15 Bil
Enterprise Value: 1.08 Bil
PE Ratio: 0
PB Ratio: 3.51
GF Score: 79/100 - Arvinas Inc to Discuss Vepdegestrant (ARV-471) Data Presented at 2023 San Antonio Breast Cancer Symposium and Plans to Expand Vepdegestrant Development Program Call TranscriptDec 06, 2023
- Arvinas Inc To Host ESMO Data Presentation Call TranscriptOct 22, 2023
- Arvinas Inc at Cantor Fitzgerald Global Healthcare Conference TranscriptSep 28, 2023
- Arvinas Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 12, 2023
- Arvinas Inc at Goldman Sachs Healthcare Conference TranscriptJun 12, 2023
- Arvinas Inc at Jefferies Healthcare Conference TranscriptJun 08, 2023
- Arvinas Inc at Bank of America Global Healthcare Conference TranscriptMay 09, 2023
- Arvinas Inc at Stifel Targeted Oncology Days (Virtual) TranscriptApr 26, 2023
- Arvinas Inc at Citi Virtual Oncology Leadership Summit TranscriptFeb 23, 2023
- Arvinas, Inc. Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-11-2023 01:30 PM TranscriptJan 11, 2023
- Arvinas Inc SABCS Event TranscriptNov 22, 2022
- Arvinas Inc at Bank of America Precision Oncology Conference TranscriptOct 03, 2022
- Arvinas Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 12, 2022
- Arvinas Inc at Citi BioPharma Conference TranscriptSep 08, 2022
- Arvinas Inc at Bank of America Healthcare Conference TranscriptMay 10, 2022
- Arvinas Inc at Cowen Health Care Conference (Virtual) TranscriptMar 07, 2022
- Arvinas Inc to Discuss the Phase 1 Dose Escalation Data and Interim Data from the Phase 2 ARDENT Trial TranscriptFeb 17, 2022
- Arvinas Inc at Guggenheim Partners Healthcare Talks Oncology Days (Virtual) TranscriptFeb 10, 2022
- Arvinas Inc ARV-471 Program Update Call TranscriptDec 10, 2021
- Arvinas Inc and Pfizer Inc Announce ARV-471 Collaboration- Conference Call TranscriptJul 22, 2021
- Arvinas Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 10, 2021
- Arvinas Inc at UBS Global Healthcare Virtual Conference TranscriptMay 25, 2021
- Arvinas Inc ASCO Data Conference Call TranscriptMay 29, 2020
- Arvinas Inc Conference Call TranscriptOct 23, 2019
Arvinas Inc at Citi Virtual Oncology Leadership Summit Transcript
Feb 23, 2023 / 06:00PM GMT
Release Date Price:
$32.94
(-4.16%)
Yigal Dov Nochomovitz
Citigroup Inc., Research Division - Director
Okay. Great. I'm Yigal Nochomovitz. I'm one of the biotech analysts at Citi. This is Citi's Virtual Oncology Leadership Summit. It's my pleasure to have with me senior management from Arvinas, Ron Peck as well as Ian Taylor. Ron, Ian, thanks so much for taking the time to chat. Great to have you.
So maybe at a high level, I think, obviously, a lot of people are very familiar with the Arvinas story, but if you could just give a quick 2- to 3-minute overview of the platform in protein degradation in the PROTAC space. And what are the key features that make Arvinas stand out in the protein degradation world relative to some of the other players. Thanks.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)